Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers.
Weir
Matthew R
MR
University of Maryland Hospital, Renal Division, N3W 143, Baltimore, MD 21202, USA. mweir@medicine.umaryland.edu
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D006801:Humans; D019808:Losartan / Q000627:therapeutic use; D012307:Risk Factors
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D019808:Losartan